NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

NeOnc Technologies (NASDAQ: NTHI) executives have purchased approximately $629,000 in company shares following positive Phase 2a results for its brain-cancer therapy NEO100. The Phase 2a study met its primary endpoint with 48.9% six-month progression-free survival compared to a 20% benchmark, with a p-value of 0.0047. The company also announced a $15 million registered direct offering and has a second program, NEO212, advancing toward Phase 2 trials.